Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials

TransfusionVolume 64, Issue 2 p. 388-399 Review Article Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials Massimo Franchini, Corresponding Author Massimo Franchini [email protected] orcid.org/0000-0002-8795-0580 Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy Correspondence Massimo Franchini, Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy. Email: [email protected]Search for more papers by this authorMario Cruciani, Mario Cruciani orcid.org/0000-0002-1641-7367 Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, ItalySearch for more papers by this authorArturo Casadevall, Arturo Casadevall orcid.org/0000-0002-9402-9167 Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, Maryland, USASearch for more papers by this authorMichael J. Joyner, Michael J. Joyner orcid.org/0000-0002-7135-7643 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USASearch for more papers by this authorJonathon W. Senefeld, Jonathon W. Senefeld orcid.org/0000-0001-8116-3538 Department of Kinesiology and Community Healthy, University of Illinois at Urbana-Champaign, Champaign, Illinois, USASearch for more papers by this authorDavid J. Sullivan, David J. Sullivan orcid.org/0000-0003-0319-0578 Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, Maryland, USASearch for more papers by this authorMatteo Zani, Matteo Zani Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, ItalySearch for more papers by this authorDaniele Focosi, Daniele Focosi orcid.org/0000-0001-8811-195X North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, ItalySearch for more papers by this author Massimo Franchini, Corresponding Author Massimo Franchini [email protected] orcid.org/0000-0002-8795-0580 Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy Correspondence Massimo Franchini, Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy. Email: [email protected]Search for more papers by this authorMario Cruciani, Mario Cruciani orcid.org/0000-0002-1641-7367 Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, ItalySearch for more papers by this authorArturo Casadevall, Arturo Casadevall orcid.org/0000-0002-9402-9167 Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, Maryland, USASearch for more papers by this authorMichael J. Joyner, Michael J. Joyner orcid.org/0000-0002-7135-7643 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USASearch for more papers by this authorJonathon W. Senefeld, Jonathon W. Senefeld orcid.org/0000-0001-8116-3538 Department of Kinesiology and Community Healthy, University of Illinois at Urbana-Champaign, Champaign, Illinois, USASearch for more papers by this authorDavid J. Sullivan, David J. Sullivan orcid.org/0000-0003-0319-0578 Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, Maryland, USASearch for more papers by this authorMatteo Zani, Matteo Zani Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, ItalySearch for more papers by this authorDaniele Focosi, Daniele Focosi orcid.org/0000-0001-8811-195X North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, ItalySearch for more papers by this author First published: 29 December 2023 https://doi.org/10.1111/trf.17701Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT Doctor Arturo Casadevall and Doctor David Sullivan declare financial conflicts of interest. All the other authors declare no competing financial interests. Supporting Information Filename Description trf17701-sup-0001-FigureS1.pptxPowerPoint 2007 presentation , 39.6 KB Figure S1. Flow diagram of literature studies selection. trf17701-sup-0002-FigureS1-S8.docxWord 2007 document , 91.4 KB Figure S2. Risk of bias summary: review authors' judgments about each risk of bias item for each included study. Figure S3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies. Figure S4. Forest plot of comparison: Convalescent Plasma vs Standard Plasma, outcome: 1.1 Any adverse reaction. Figure S5. Forest plot of comparison: Convalescent Plasma vs Standard Plasma, outcome: 1.2 Serious adverse reactions. Figure S6. Forest plot of comparison: Convalescent Plasma vs Standard Plasma, outcome: 1.4 Treatment-related adverse reactions (any grade). Figure S7. Forest plot of comparison: Convalescent Plasma vs Standard Plasma, outcome: 1.4 Treatment-related adverse reactions (serious). Figure S8. Forest plot of comparison: Convalescent Plasma vs Standard Plasma, outcome: 1.6 Venous and arterial thrombotic events. trf17701-sup-0003-TableS1.docxWord 2007 document , 42.5 KB Table S1. Analysis of RCTs on the safety of COVID-19 convalescent plasma. trf17701-sup-0004-TableS2.docxWord 2007 document , 21.3 KB Table S2. Randomized controlled trials excluded from the systematic review. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020; 105: 2834–2840. 10.3324/haematol.2020.261784 CASPubMedWeb of Science®Google Scholar 2Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020; 95(9): 1888–1897. 10.1016/j.mayocp.2020.06.028 CASPubMedWeb of Science®Google Scholar 3Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic. Drug Discov Today. 2021; 26(2): 593–603. 10.1016/j.drudis.2020.11.025 CASPubMedWeb of Science®Google Scholar 4Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023; 6(1):e2250647. 10.1001/jamanetworkopen.2022.50647 PubMedWeb of Science®Google Scholar 5Franchini M, Liumbruno GM, Piacentini G, Glingani C, Zaffanello M. The three pillars of COVID-19 convalescent plasma therapy. Life (Basel). 2021; 11: 354. CASPubMedWeb of Science®Google Scholar 6Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022; 35(3):e0020021. 10.1128/cmr.00200-21 PubMedWeb of Science®Google Scholar 7Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021; 10:e69866. 10.7554/eLife.69866 CASPubMedWeb of Science®Google Scholar 8Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, et al. Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study. PLoS Med. 2021; 18(12):e1003872. 10.1371/journal.pmed.1003872 CASPubMedWeb of Science®Google Scholar 9Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023; 2(2):CD013600. PubMedGoogle Scholar 10Franchini M, Cruciani M. How safe is COVID-19 convalescent plasma? Mayo Clin Proc. 2021; 96(8): 2279–2281. 10.1016/j.mayocp.2021.06.011 CASPubMedWeb of Science®Google Scholar 11Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. 10.1136/bmj.n71 PubMedGoogle Scholar 12 JP Higgins, S Green, editors. Cochrane Handbook for Systematic Reviews of Interventions—Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://www.cochranehandbook.org Google Scholar 13Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: presenting results and ‘Summary of findings’ tables. In: JP Higgins, S Green, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). London (UK): The Cochrane Collaboration; 2011 Available from handbook.cochrane.org Google Scholar 14Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is ‘quality of evidence’ and why is it important to clinicians? BMJ. 2008; 336: 995–998. 10.1136/bmj.39490.551019.BE PubMedWeb of Science®Google Scholar 15AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep. 2021; 11(1): 9927. 10.1038/s41598-021-89444-5 CASPubMedWeb of Science®Google Scholar 16Baldeón ME, Maldonado A, Ochoa-Andrade M, Largo C, Pesantez M, Herdoiza M, et al. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Transfus Med. 2022; 32(2): 153–161. 10.1111/tme.12851 PubMedWeb of Science®Google Scholar 17Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021; 131(24):e155114. 10.1172/JCI155114 CASPubMedWeb of Science®Google Scholar 18Bargay-Lleonart J, Sarubbo F, Arrizabalaga M, Guerra JM, Borràs J, El Haji K, et al. Reinforcement of the standard therapy with two infusions of convalescent plasma for patients with COVID-19: a randomized clinical Trial. J Clin Med. 2022; 11(11): 3039. 10.3390/jcm11113039 CASPubMedWeb of Science®Google Scholar 19Beltran Gonzalez JL, Gonzalez Gamez M, Mendoza Enciso EA, Esparza Maldonado RJ, Hernandez Palacios D, Duenas Campos S, et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv. 2021. https://doi.org/10.1101/2021.03.28.21254507 10.1101/2021.03.28.21254507 Google Scholar 20Bennett-Guerrero E, Romeiser JL, Talbot LR, Ahmed T, Mamone LJ, Singh SM, et al. Stony brook medicine COVID plasma Trial group. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized Trial. Crit Care Med. 2021; 49(7): 1015–1025. 10.1097/CCM.0000000000005066 CASPubMedWeb of Science®Google Scholar 21Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021; 131(20):e152264. 10.1172/JCI152264 PubMedWeb of Science®Google Scholar 22Thorlacius-Ussing L, Brooks PT, Nielsen H, Jensen BA, Wiese L, Sækmose SG, et al. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Sci Rep. 2022; 12:16385. 10.1038/s41598-022-19629-z CASPubMedWeb of Science®Google Scholar 23Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021; 27: 2012–2024. 10.1038/s41591-021-01488-2 CASPubMedWeb of Science®Google Scholar 24Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021; 12(1): 3189. 10.1038/s41467-021-23469-2 CASPubMedWeb of Science®Google Scholar 25Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, Malo de Molina R, Torres F, et al. ConPlas-19 study group. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021; 131(20):e152740. 10.1172/JCI152740 CASPubMedWeb of Science®Google Scholar 26Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. CONTAIN COVID-19 consortium for the CONTAIN COVID-19 study group. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical Trial. JAMA: Intern Med. 2022; 182(2): 115–126. 10.1001/jamainternmed.2021.6850 CASPubMedWeb of Science®Google Scholar 27Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, et al. CONV-ERT group. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022; 10(3): 278–288. 10.1016/S2213-2600(21)00545-2 CASPubMedWeb of Science®Google Scholar 28Bajpai M, Maheshwari A, Dogra V, Kumar S, Gupta E, Kale P, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open. 2022; 12(4):e055189. 10.1136/bmjopen-2021-055189 PubMedWeb of Science®Google Scholar 29Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al. SIREN-C3PO investigators. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021; 385(21): 1951–1960. 10.1056/NEJMoa2103784 CASPubMedWeb of Science®Google Scholar 30Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the donated antibodies working against nCoV (DAWn-plasma) trial. Trials. 2020; 21(1): 981. 10.1186/s13063-020-04876-0 CASPubMedWeb of Science®Google Scholar 31Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023; 4(1): 96–107. CASPubMedGoogle Scholar 32de Santis GC, Oliveira L, Garibaldi P, Almado C, Croda J, Arcanjo G, et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerg Infect Dis. 2022; 28(3): 548–555. 10.3201/eid2803.212299 PubMedWeb of Science®Google Scholar 33Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egypt J Anaesth. 2020; 36(1): 264–272. 10.1080/11101849.2020.1842087 Web of Science®Google Scholar 34Holm K, Lundgren MN, Kjeldsen-Kragh J, Ljungquist O, Böttiger B, Wikén C, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Res Notes. 2021; 14(1): 440. 10.1186/s13104-021-05847-7 CASPubMedWeb of Science®Google Scholar 35Kirenga B, Byakika-Kibwika P, Muttamba W, Kayongo A, Loryndah NO, Mugenyi L, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res. 2021; 8(1):e001017. 10.1136/bmjresp-2021-001017 PubMedWeb of Science®Google Scholar 36Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020; 324(5): 460–470. 10.1001/jama.2020.10044 CASPubMedWeb of Science®Google Scholar 37Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021; 384(7): 610–618. 10.1056/NEJMoa2033700 CASPubMedWeb of Science®Google Scholar 38O'Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021; 131(13):e150646. 10.1172/JCI150646 PubMedWeb of Science®Google Scholar 39Self WH, Wheeler AP, Stewart TG, Schrager H, Mallada J, Thomas CB, et al. Neutralizing COVID-19 convalescent plasma in adults hospitalized with COVID-19: a blinded, randomized, placebo-controlled trial. Chest. 2022; 162(5): 982–994. 10.1016/j.chest.2022.06.029 CASPubMedWeb of Science®Google Scholar 40Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371:m3939. 10.1136/bmj.m3939 PubMedGoogle Scholar 41Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J. 2022; 59(2):2101471. 10.1183/13993003.01471-2021 CASPubMedWeb of Science®Google Scholar 42Manzini PM, Ciccone G, De Rosa FG, Cavallo R, Ghisetti V, D'Antico S, et al. PLACO COVID study group. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. BMC Infect Dis. 2022; 22(1): 879. 10.1186/s12879-022-07716-5 PubMedWeb of Science®Google Scholar 43Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021; 384(7): 619–629. 10.1056/NEJMoa2031304 CASPubMedWeb of Science®Google Scholar 44Pouladzadeh M, Safdarian M, Eshghi P, Abolghasemi H, Bavani AG, Sheibani B, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med. 2021; 16(8): 2181–2191. 10.1007/s11739-021-02734-8 PubMedWeb of Science®Google Scholar 45van den Berg K, Glatt TN, Vermeulen M, Little F, Swanevelder R, Barrett C, et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-patient trial). Sci Rep. 2022; 12(1): 2552. 10.1038/s41598-022-06221-8 PubMedGoogle Scholar 46Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Raychaudhuri D, et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat Commun. 2022; 13(1): 383. 10.1038/s41467-022-28064-7 CASPubMedWeb of Science®Google Scholar 47 RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021; 397(10289): 2049–2059. 10.1016/S0140-6736(21)00897-7 PubMedWeb of Science®Google Scholar 48 Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2021; 326(17): 1690–1702. 10.1001/jama.2021.18178 PubMedWeb of Science®Google Scholar 49Rojas M, Rodríguez Y, Hernández JC, Díaz-Coronado JC, Vergara JAD, Vélez VP, et al. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infect Dis. 2022; 22(1): 575. 10.1186/s12879-022-07560-7 CASPubMedWeb of Science®Google Scholar 50Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, et al. Transfusing convalescent plasma as post-exposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a double-blinded, phase 2 randomized, controlled trial. Clin Infect Dis. 2023; 76(3): e477–e486. 10.1093/cid/ciac372 CASPubMedWeb of Science®Google Scholar 51Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022; 386(18): 1700–1711. 10.1056/NEJMoa2119657 CASPubMedWeb of Science®Google Scholar 52Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical Trial. JAMA Netw Open. 2021; 4(11):e2136246. 10.1001/jamanetworkopen.2021.36246 PubMedWeb of Science®Google Scholar 53Ventura-Enríquez Y, Cabello-Gutiérrez C, Pérez-Calatayud ÁA, Cortina-De la Rosa E, Fareli-González CJ, Castillo-Juárez P, et al. Convalescent plasma to treat COVID-19: a two-center, randomized, double-blind clinical Trial. Life (Basel). 2022; 12(11): 1767. CASPubMedWeb of Science®Google Scholar 54Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020; 130(9): 4791–4797. 10.1172/JCI140200 CASPubMedWeb of Science®Google Scholar 55 FDA. Convalescent plasma EUA Fact Sheet for health care providers. August 23, 2020. Accessed August 25, 2020. Available from: https://www.fda.gov/media/141478/download Google Scholar 56Li PY, Yu P, Li A, Khalid F, Laureano ML, Crowther MA. Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: efficacy and risk of thromboembolism. Res Pract Thromb Haemost. 2023; 7(2):100068. 10.1016/j.rpth.2023.100068 PubMedWeb of Science®Google Scholar 57Franchini M, Marano G, Cruciani M, Mengoli C, Pati I, Masiello F, et al. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020; 7(4): 357–363. 10.1515/dx-2020-0078 CASPubMedWeb of Science®Google Scholar 58Dai W, Gu H, Hao S. Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19. Blood Sci. 2020; 2(3): 71–75. 10.1097/BS9.0000000000000047 PubMedGoogle Scholar 59Focosi D, Franchini M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol. 2021; 28(2): 132–134. 10.1016/j.tracli.2021.02.005 CASPubMedWeb of Science®Google Scholar 60Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020; 584(7821): 353–363. 10.1038/s41586-020-2538-8 CASPubMedWeb of Science®Google Scholar 61Ricke DO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. 2021; 12:640093. 10.3389/fimmu.2021.640093 CASPubMedWeb of Science®Google Scholar 62Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. HGID lab; NIAID-USUHS immune response to COVID group; COVID clinicians; COVID-STORM clinicians; imagine COVID group; French COVID cohort study group; milieu Intérieur consortium; CoV-contact cohort; Amsterdam UMC COVID-19 biobank; COVID human genetic effort. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515):eabd4585. 10.1126/science.abd4585 CASPubMedWeb of Science®Google Scholar 63Cognasse F, Hamzeh-Cognasse H, Rosa M, Corseaux D, Bonneaudeau B, Pierre C, et al. Inflammatory markers and auto-abs to type I IFNs in COVID-19 convalescent plasma cohort study. EBioMedicine. 2023; 87:104414. 10.1016/j.ebiom.2022.104414 CASPubMedWeb of Science®Google Scholar 64McDyer JF, Azimpouran M, Durkalski-Mauldin VL, Clevenger RG, Yeatts SD, Deng X, et al. COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response. JCI. Insight. 2023; 8:e167890. Web of Science®Google Scholar 65Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313(5): 471–482. 10.1001/jama.2015.12 CASPubMedWeb of Science®Google Scholar 66Carson JL, Ness PM, Pagano MB, Philipp CS, Bracey AW Jr, Brooks MM, et al. Plasma trial: pilot randomized clinical trial to determine safety and efficacy of plasma transfusions. Transfusion. 2021; 61(7): 2025–2034. 10.1111/trf.16508 CASPubMedWeb of Science®Google Scholar 67Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, et al. Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. Clin Infect Dis. 2023; 76(11):2018-2024. 10.1093/cid/ciad066 PubMedWeb of Science®Google Scholar 68Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan DJ, et al. Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy. Expert Rev Respir Med. 2023; 17(5): 381–395. 10.1080/17476348.2023.2208349 CASPubMedWeb of Science®Google Scholar Citing Literature Volume64, Issue2February 2024Pages 388-399 ReferencesRelatedInformation